Global Pharmaceuticals

How mature is each company’s AI governance? We score it from primary evidence (regulatory filings, job postings, and governance disclosures), never from press releases.

How we score this

91%

Board Oversight

Boards enact oversight more than they announce it — substance leads signal.

91% carry an operative board mechanism vs 68% that only state one · +23pp · Nasdaq-100 · n=66

Governance Is Not Bought

Firm size and resources explain almost none of it. Governance maturity is not a function of how big you are.

Apparatus depth vs. size: R²≈0.06 · confound-independent

15%

Who Actually Staffs It

Most "AI-governance" roles are mislabeled build roles. Only ~15% actually govern.

Role-anchored govern-share · covered panel · bank-weighted

0.82κ

Media DO / SAY Reversal

Some govern quietly; others announce it loudly. The two rarely coincide.

M-channel DO vs SAY · agreement κ=0.82

+25pp

Substance Leads or Lags

On the board channel, substance comes before the announcement, not after.

Board substance premium +25pp · cross-channel timing pending

Firm

Ranked by

Ethical Advancement

L4 · Sustained

NovartisNVS

68.6

L3 · Emerging

Sanofi

65.3

MerckMRK

64.9

AmgenAMGN

64.0

AstraZenecaAZN

63.6

GSK plc

63.6

Johnson & JohnsonJNJ

60.9

Novo Nordisk

60.1

AbbVieABBV

58.3

Roche Holding AGROG

57.8

Eli Lilly and Company

56.5

Bristol-Myers SquibbBMY

55.9

Gilead SciencesGILD

53.5

Takeda Pharmaceutical Company Limited

51.3

Ethical AdvancementL3–L414 firms

L4 · Sustained

68.62

L3 · Emerging

65.33

64.91

63.97

63.59

63.58

60.85

60.11

58.26

57.77

56.51

55.85

53.54

51.26